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TGF-β induces MafK and Bach1 to suppress HO-1 
Background: TGF-β suppresses early 
carcinogenesis but accelerates malignant 
progression by activating invasion and metastasis. 
HO-1 is induced in response to oxidative stress 
and protects cells from oxidative injury. 
Results: TGF-β suppresses tBHQ-inducible 
expression of HO-1 through induction of MafK 
and Bach1. 
Conclusion: TGF-β suppresses a protective 
response to electrophiles.  
Significance: This work provides the first 
evidence that TGF-β affects electrophilic 
responses. 
 
SUMMARY 
Transforming growth factor-β  (TGF-β) has 
multiple functions in embryogenesis, adult 
homeostasis, tissue repair, and development of 
cancer. Here, we report that TGF-β  suppresses 
the transcriptional activation of the heme 
oxygenase-1 gene (HO-1), which is implicated 
in protection against oxidative injury and lung 
carcinogenesis. HO-1 is a target of the oxidative 
stress-responsive transcription factor, Nrf2. 
TGF-β  did not affect the stabilization or 
nuclear accumulation of Nrf2 after stimulation 
with electrophiles. Instead, TGF-β  induced 
expression of transcription factors MafK and 
Bach1. Enhanced expression of either MafK or 
Bach1 was enough to suppress the 
electrophile-inducible expression of HO-1 even 
in the presence of accumulated Nrf2 in the 
nucleus. Knockdown of MafK and Bach1 by 
siRNA abolished TGF-β-dependent 
suppression of HO-1. Furthermore, chromatin 
immunoprecipitation assays revealed that Nrf2 
substitutes for Bach1 at the antioxidant 
response elements (AREs; E1 and E2), which 
are responsible for the induction of HO-1 in 
response to oxidative stress. On the other hand, 
pretreatment with TGF-β  suppressed binding 
of Nrf2 to both E1 and E2 but marginally 
increased the binding of MafK to E2 together 
with Smads. As TGF-β  is activated after tissue 
injury and in the process of cancer 
development, these findings suggest a novel 
mechanism by which damaged tissue becomes 
vulnerable to oxidative stress and xenobiotics.  
 
Transforming growth factor-β (TGF-β) 
regulates multiple biological functions such as cell 
proliferation, differentiation, apoptosis, and 
morphogenesis (1, 2). Upon ligand binding, type II 
serine/threonine kinase receptors activate type I 
receptors, and activated type I receptors 
phosphorylate Smad proteins. Phosphorylated 
receptor-regulated Smads (R-Smads; Smad2 and 
Smad3) form heteromeric complexes with 
common partner Smad (Co-Smad; Smad4) and 
accumulate in the nucleus. Activated Smad 
complexes regulate expression of target genes by 
binding to specific DNA sequences together with 
various cobinding transcription factors and 
recruiting coactivators or corepressors (3). 
Differential expression of cobinding transcription 
factors contributes to the cell type- and 
context-dependent cellular responses to TGF-β.  
TGF-β is a potent inhibitor of epithelial cell 
proliferation; therefore, it acts as a tumor 
suppressor in the early stages of carcinogenesis. 
On the other hand, cancer cells develop resistance 
to TGF-β-inducible growth inhibition in the 
advanced stages of carcinogenesis. At these later 
stages, TGF-β promotes epithelial–mesenchymal 
transition, invasion, and metastasis in certain types 
of cancer cells without TGF-β receptor 
abnormalities (4). Therefore, TGF-β is thought to 
act as a double-edged sword in cancer 
development (5). However, the multifunctional 
effects of TGF-β on cancer initiation and 
progression have not been fully elucidated.  
Detoxification and export of xenobiotics are 
crucial for the maintenance of cellular homeostasis 
and protection against carcinogenic agents (6). 
Nrf2, a member of the cap ‘n’ collar (CNC) family 
of basic region leucine zipper (b-Zip) transcription 
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factors (7), is a key transcriptional regulator of 
detoxification enzymes, transporters, and 
antioxidative molecules. Nrf2 forms heterodimers 
with small Maf proteins (MafF, MafG, and MafK), 
binds to antioxidant response elements (ARE), and 
activates transcription of target genes. Mice 
lacking Nrf2 fail to induce phase II detoxifying 
enzymes and antioxidative molecules in response 
to oxidative stress, indicating that Nrf2 has a 
critical role in cellular defense against xenobiotics 
and oxidative stress (8). 
ARE-mediated transcriptional activities are 
regulated by the combinations and relative levels 
of CNC molecules and small Maf proteins. The 
Nrf2-small Maf heterodimer is essential for the 
activation of ARE-mediated transcription. On the 
other hand, small Maf homodimers have been 
reported to suppress ARE-mediated transcription 
(7). Other CNC molecules, including Bach1, form 
heterodimers with small Maf proteins and 
suppress ARE-mediated transcription (9). For 
example, the MafK-Bach1 heterodimer interacts 
with AREs in the enhancer region of the heme 
oxygenase-1 gene (HO-1) and suppresses its 
transcription. Heme, an inducer of HO-1, 
displaces Bach1 from the AREs, which is 
followed by binding of Nrf2 to the AREs and 
increases in HO-1 expression (10-12). HO-1 
catalyzes the rate-limiting step in heme catabolism 
and generates carbon monoxide, ferric iron, and 
biliverdin. Carbon monoxide and ferric iron can 
activate Nrf2, suggesting that HO-1 acts as a 
cytoprotective factor in both suppression of 
oxidative stress and activation of Nrf2 (13-15).  
In this study, we examined the effect of TGF-β 
on the expression of HO-1. We found that TGF-β 
induces expression of MafK and Bach1 and that 
these genes are essential for suppression of HO-1 
by TGF-β signaling. 
 
EXPERIMENTAL PROCEDURES 
Cells and culture – 293T and NMuMG cells were 
obtained from the American Type Culture 
Collection. These cells were cultured in 
Dulbecco’s modified Eagle’s medium (Invitrogen) 
supplemented with 10% fetal bovine serum (FBS) 
and 1% penicillin-streptomycin solution (Gibco). 
Mouse mammary carcinoma JygMC(A) cells were 
cultured as described previously (16). 
DNA constructs – Expression constructs 
encoding ALK5T204D and FLAG-Smads (17, 18) 
and the luciferase reporters pNQO1-ARE-luc (19) 
and pHO1-luc (20) were described previously. 
cDNAs for Nrf2, MafF, MafG, MafK, and Bach1 
were cloned into the pcDEF3 vector before use. 
For establishment of cells stably expressing 
FLAG-MafK or FLAG-Bach1, corresponding 
cDNAs were cloned into the pCAGIP vector (21). 
DNA transfection – 293T and NMuMG cells 
were transfected using FuGENE 6 transfection 
reagent (Roche Diagnostics) or Lipofectamine 
2000 (Invitrogen) following the manufacturers’ 
recommendations. For establishment of cell lines 
stably expressing MafK or Bach1, NMuMG cells 
were transfected with pCAGIP-FLAG-MafK or 
pCAGIP-FLAG-Bach1, respectively, and cloned 
and maintained in the presence of puromycin (1 
µg/ml, Sigma). 
  RNA interference – NMuMG and JygMC(A) 
cells were transfected with 40 nM of small 
interfering RNA (siRNA) directed against MafK 
or Bach1 using Lipofectamine 2000 (Invitrogen). 
In case of double knockdown of MafK and Bach1, 
cells were transfected with 40 nM of each siRNA. 
Sequences of siRNA are listed in Table 1. Control 
siRNA was purchased from Invitrogen (StealthTM 
RNAi NEGATIVE UNIVERSAL CONTROL 
Medium). A pSUPER-puro vector (Oligoengine) 
expressing a short hairpin RNA against human 
and mouse Smad4 (pSUPER-sh-Smad4) was 
described previously (22). NMuMG cells 
transfected with pSUPER-sh-Smad4 were cloned 
and maintained in the presence of puromycin (1 
µg/ml). 
Luciferase assay – Luciferase activities were 
measured by a Luciferase Reporter Assay System 
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(Promega) using a luminometer (MicroLumat, 
Berthold). The obtained luciferase activities were 
normalized to β-galactosidase activities of 
cotransfected pcDNA1.2/V5-GW/lacZ 
(Invitrogen). 
Reverse transcription and polymerase chain 
reaction (RT-PCR) – Total RNA was prepared 
using ISOGEN (Nippon Gene). RT was performed 
using High Capacity RNA-to-cDNA Master Mix 
(Applied Biosystems), and PCR, using Ex Taq 
Polymerase (Takara Bio). PCR primers are listed 
in Table 2. 
Immunoprecipitation and immunoblot analysis 
– Cells were solubilized in lysis buffer (20 mM 
Tris-HCl pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 
2000 KIU/ml aprotinin, 1 µg/ml leupeptin). After 
clearing by centrifugation, total cell lysates or 
immunoprecipitates obtained using the indicated 
antibodies were subjected to sodium dodecyl 
sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE). Proteins were electrotransferred to 
a mixed ester nitrocellulose membrane (Hybond-C 
Extra, GE Healthcare) and subjected to 
immunoblot analysis. Anti-Nrf2 (H-300, Santa 
Cruz), anti-HO-1 (Stressgene), anti-NQO1 
(Abcam), anti-α-tubulin (Cell Signaling 
Technology), anti-β-actin (Sigma), 
anti-hemagglutinin (HA) (3F10, Roche Applied 
Science), anti-FLAG (M2, Sigma), anti-Smad2/3 
(clone 18, Transduction Laboratories), anti-Smad4 
(Santa Cruz), anti-phospho-Smad2 (23), 
anti-MafK (24), and anti-Bach1 (11) were used as 
primary antibodies for the immunoblot analysis. 
Reacted antibodies were detected using 
SuperSignal West Dura Extended Duration 
Substrate (Thermo Scientific). For reblotting, 
membranes were stripped according to the 
manufacturer’s protocol. 
Immunofluorescence microscopy – To detect 
Nrf2 and Smad2, NMuMG cells were fixed in 4% 
formaldehyde. The fixed cells were permeabilized, 
and nonspecific protein binding was blocked by 
1% bovine serum albumin (BSA) and 0.3% 
Triton-X100 in phosphate buffered saline (PBS). 
Cells were incubated with a mixture of 
anti-Smad2 (BD Transduction Laboratories) and 
anti-Nrf2 (25) antibodies and then with Texas 
Red-conjugated anti-mouse IgG (Molecular 
Probes; Invitrogen), followed by Alexa 
488-conjugated anti-rat IgG (Molecular Probes; 
Invitrogen). The nuclei were counterstained with 
DAPI (4’, 6-diamidino-2-phenylindole). 
  Cell fractionation – Cells were washed with 
PBS and treated with ice-cold hypotonic buffer 
(20% glycerol, 20 mM HEPES pH 7.6, 10 mM 
NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.1% 
Triton-X, 25 mM β-glycerophosphate, 1 mM 
phenylmethylsulfonyl fluoride, 1 mM 
dithiothreitol, 20,000 KIU/ml aprotinin). Nuclei 
(pellet) and cytosol (supernatant) were separated 
by centrifugation (16,000g, 5 min). Nuclei were 
resuspended in SDS-PAGE sample buffer. 
Proteins in cytosolic fractions were precipitated 
with methanol and resuspended in SDS-PAGE 
sample buffer.  
  DNA affinity precipitation (DNAP) – Cells were 
lysed in 1% Nonidet P-40, 150 mM NaCl, 20 mM 
Tris-HCl (pH 7.5), 2000 KIU/ml Aprotinin, and 1 
µg/ml Leupeptin. Equal amounts of lysate protein 
were incubated with biotinylated double-stranded 
DNA oligonucleotides and poly dI-dC (Roche) at 
4°C for one hour. DNA-protein complexes were 
captured with streptavidin-agarose for one hour, 
and subjected to immunoblotting. The sequence of 
HO-1-ARE probe was as follows; sense: 
5′-Bio-TTCGCTGAGTCATGGTTCCC-3′, 
antisense: 5′-GGGAACCATGACTCAGCGAA-3′ 
(20). 
Chromatin immunoprecipitation (ChIP) – ChIP 
was performed as previously described (17), with 
modifications. Cells were treated with TGF-β (5 
ng/ml) one hour before treatment with 
tert-butylhydroquinone (tBHQ, 25 µM). After 
crosslinking with 1% formaldehyde at 37°C for 15 
min, cells were suspended in 500 µl nuclear lysis 
buffer (1% SDS, 50 mM Tris-HCl pH 8.1, 10 mM 
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EDTA, 20000 KIU/ml aprotinin, 1 µg/ml 
leupeptin) and sonicated. Soluble chromatin was 
diluted with 9 volumes of dilution buffer for 
immunoprecipitation (16.7 mM Tris-HCl pH 8.1, 
1.2 mM EDTA, 167 mM NaCl, 0.01% SDS, 1.1% 
Triton X-100, 20000 KIU/ml aprotinin, 1 µg/ml 
leupeptin) and incubated with normal rabbit IgG, 
anti-Nrf2 (H-300, Santa Cruz), anti-MafK (24), 
anti-Bach1 (11), or anti-Smad2/3 (clone 18, 
Transduction Laboratories) antibodies with 
end-over-end rotation at 4°C overnight, followed 
by incubation 	  with 25 µl of Dynabeads® 
Protein A (Invitrogen) at 4°C for one hour. DNA 
was extracted from the Dynabeads by means of 
phenol-chloroform extraction. PCR was 
performed using Ex Taq Polymerase. The PCR 
primers are described in Table 3. Otherwise, 
quantitative PCR was performed using qPCR 
MasterMix for SYBER Green I (Applide 
Biosystems) and the ABI7500 Fast Sequence 
Detection system. All samples were run in 
triplicate in each experiment. Primer sequences 
are listed in Table 4. 
 
RESULTS 
TGF-β suppresses electrophile-inducible 
expression of HO-1 – To examine the effect of 
TGF-β on expression of HO-1, NMuMG cells 
were treated with tert-butyl hydroquinone (tBHQ) 
in the absence or presence of TGF-β signaling. 
mRNA levels of HO-1 were highly increased 4 
hours after tBHQ stimulation (Fig. 1A, lanes 2, 3). 
However, pretreatment of the cells with TGF-β 
significantly reduced the induction (Fig. 1A, lanes 
4, 5). TGF-β alone had no detectable effect on the 
basal expression levels of HO-1 (Fig. 1A, lanes 6, 
7). A representative result of the densitometric 
quantification of normalized mRNA levels is 
shown in the right panel of Figure 1A. 
TGF-β-mediated suppression of HO-1 was 
examined also in the protein levels (Fig. 1B). 
These results indicate that TGF-β suppresses 
tBHQ-inducible expression of HO-1 in NMuMG 
cells.  
  TGF-β does not affect the stabilization or 
nuclear accumulation of Nrf2 – To examine how 
TGF-β affects HO-1 expression, we examined the 
expression and subcellular localization of Nrf2 
proteins in NMuMG cells. Since Nrf2 activates the 
transcription of HO-1, we assumed that TGF-β 
would affect the accumulation or nuclear 
translocation of Nrf2. However, as shown in 
Figure 2, neither the stabilization (Fig. 2A) nor the 
nuclear localization of Nrf2 (Fig. 2B, 2C) was 
affected by TGF-β.  
TGF-β induces MafK and Bach1 – Nrf2 
activates transcription of target genes by binding 
to AREs together with small Maf proteins. 
However, if small Maf levels rise exceedingly, 
small Maf homodimers can compete with 
Nrf2-small Maf heterodimers for the binding to 
AREs (7). Otherwise, heterodimers of small Mafs 
and other CNC-type transcriptional regulators 
such as Bach1 can compete for the binding (9). 
Since TGF-β did not affect the nuclear 
accumulation of Nrf2, we next examined the effect 
of TGF-β on the expression of small Mafs and 
Bach1 and found that TGF-β increased MafK and 
Bach1 in both the mRNA and the protein levels 
(Fig. 3A, 3B). Induction of MafK and Bach1 was 
suppressed by a TGF-β type I receptor kinase 
inhibitor, SD-208 (Fig. 3C). 
  MafK and Bach1 regulate induction of HO-1 – 
We next examined the effect of MafF, MafG, and 
MafK on pHO1-luc activities. Transiently 
expressed MafG and MafK but not MafF 
suppressed the reporter activities (Fig. 4A). MafF, 
MafG, and MafK all formed heterodimers with 
Nrf2 (Fig. 4B), but when small Maf proteins were 
independently expressed, MafK and MafG but not 
MafF bound to HO-1 ARE DNA fragments (Fig. 
4C). We then established NMuMG cell lines with 
stable expression of MafK, MafG or Bach1. 
Binding of MafK and MafG to HO-1 ARE (E2) 
was confirmed by chromatin immunoprecipitation 
(Fig. 4D). In functional analyses, both tBHQ and 
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diethyl maleate (DEM) induced HO-1 expression 
in NMuMG cells. However, these effects were 
completely blocked by overexpression of MafK 
(Fig. 5A, 5B). MafK also decreased pHO1-luc 
activities in both the absence and the presence of 
tBHQ or DEM (Fig. 5C). On the other hand, 
reduction of MafK by siRNA strikingly enhanced 
tBHQ-inducible expression of HO-1 mRNA (Fig 
5D). However, stable overexpression of MafG did 
not suppressed tBHQ- and DEM-inducible 
expression of HO-1 (Suppl. Fig. 2). We also 
established NMuMG cells stably expressing 
FLAG-Bach1 (Fig. 5E). Bach1 had a nearly 
identical effect as that of MafK on HO-1 
expression (Fig. 5E-H), except for a stronger 
induction of HO-1 in the absence of both 
electrophiles and TGF-β (Fig. 5H). Furthermore, 
double-knockdown of MafK and Bach1 highly 
increased both the basal and the tBHQ-inducible 
expression of HO-1 and abolished the suppressive 
effect of TGF-β on tBHQ-inducible HO-1 
expression (Fig. 5I). Endogenous MafK and 
Bach1 suppressed HO-1 also in breast cancer cells. 
Knockdown of MafK or Bach1 in JygMC(A) cells 
clearly increased expression of HO-1 (Fig. 5J). 
  Recruitment of Nrf2, MafK, and Bach1 to ARE 
sites in the HO-1 promoter – ARE sites (E1 and 
E2) in the promoter region of HO-1 are essential 
for its transcriptional regulation. To determine 
whether changes in HO-1 expression are 
associated with altered binding of Nrf2, MafK, 
and Bach1 to ARE sites in vivo, we performed 
chromatin immunoprecipitation assays. When 
cells were treated with tBHQ, Nrf2 binding to 
both E1 and E2 increased, mainly to E1. These 
interactions were reduced when cells were treated 
with TGF-β before tBHQ stimulation (Fig. 6A). 
Binding of MafK to E1 and E2 increased after 
tBHQ-stimulation together with Nrf2, but its 
binding to E2 was not decreased by TGF-β 
treatment (Fig. 6B). In contrast, Bach1 binding to 
E2 was highest in the absence of tBHQ and 
reduced when cells were treated with tBHQ (Fig. 
6C). 
  Binding of Smad3 and MafK on ARE sites in the 
HO-1 promoter – Binding of MafK or Bach1 and 
Smad3 was examined by coprecipitation assays. 
Both MafK and Bach1 bound to Smad3. MafK 
bound to Smad3 in the presence of TGF-β 
signaling. On the other hand, Bach1 bound to 
Smad3 in the absence of TGF-β signaling (Fig. 7A, 
7B). Binding of Smad2/3 on ARE (E2) in the 
promoter region of HO-1 was detected by 
chromatin immunoprecipitation assays in the 
presence of TGF-β signaling (Fig. 7C). 
 
DISCUSSION 
  In this study, we proved that TGF-β suppresses 
the electrophile-inducible transcriptional 
activation of HO-1. This is the first report on the 
regulation of the Nrf2-mediated oxidative stress 
responses by TGF-β signaling. Intriguingly, 
TGF-β did not reduce the nuclear accumulation of 
Nrf2 provoked by electrophiles, but the 
recruitment of Nrf2 to AREs (E1 and E2) in the 
promoter region of HO-1 was clearly suppressed 
by TGF-β. Consistent with the previous report that 
MafK-Bach1 heterodimers repress HO-1 
expression (12), knockdown of MafK and Bach1 
enhanced HO-1 expression and abolished the 
suppressive effect by TGF-β (Fig. 5I). These 
results suggest that TGF-β signaling generally 
antagonizes cytoprotective responses mediated by 
the Keap1-Nrf2 system. Therefore, we further 
investigated the effect of TGF-β on Nrf2-mediated 
activation of other Nrf2 target genes. 
NAD(P)H:quinone oxidoreductase 1 (NQO1) and 
the heavy and light chains of γ-glutamylcysteine 
synthetase (GCS-H and GCS-L, respectively) 
were examined, and all of these target genes were 
suppressed by TGF-β, although the extents of the 
suppression were different in different genes (data 
not shown). Furthermore, the constitutively active 
TGF-β type I receptors ALK5T204D significantly 
suppressed Nrf2-mediated activation of 
pNQO1-ARE-luc together with Smad3 (data not 
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shown). The reporter activity was further 
suppressed by the addition of Smad4. These 
results suggested that TGF-β suppresses the 
transcriptional activity of Nrf2 through activation 
of the Smad signaling pathway. However, 
suppression of these Nrf2-target genes was not 
canceled by knockdown of MafK and Bach1 (data 
not shown). HO-1 was the only gene in which 
suppression by TGF-β was canceled by 
knockdown of MafK and Bach1. Therefore, 
TGF-β probably suppresses different target genes 
in different molecular mechanisms. Consistent 
with this notion, both HO-1 and NQO-1 are 
regulated by Nrf2 and these genes contain ARE 
sites in their promoter regions, but Bach1 interacts 
specifically with AREs in HO-1. Subtle 
differences in AREs or their flanking sequences 
affect the binding affinities of the Maf-containing 
dimers, resulting in the different contributions of 
each dimer to the ARE-dependent gene regulation. 
Indeed, both Nrf2/MafG heterodimer and MafG 
homodimer bind to the consensus Maf recognition 
element with high affinity but bind differentially 
to the suboptimal binding sequences degenerated 
from the consensus (26, 27). Different Maf 
complexes may be differently regulated by TGF-β 
signaling.  
  A discrepancy between the nuclear 
accumulation and transcriptional activity of Nrf2 
was reported. When human aortic endothelial cells 
were exposed to oscillating flow, Nrf2 
accumulated in the nuclei but did not activate 
stress response genes. In contrast, when the cells 
were exposed to laminar flow, Nrf2 accumulated 
in the nuclei and activated its target genes (28). 
The analogous finding of the current study suggest 
that levels of small Mafs and Bach1 or other 
related transcriptional factors might be involved in 
nuclear regulation of Nrf2 activities. 
  The functional analyses described above clearly 
indicated that MafK and Bach1 are essential for 
the suppression of HO-1 by TGF-β signaling (Fig. 
5). ChIP analyses (Fig. 6) also revealed that tBHQ 
treatment substitutes Nrf2 for Bach1 in the E1 and 
E2 elements of HO-1 and that TGF-β reduces 
Nrf2 in both elements. However, TGF-β signaling 
increased MafK binding only marginally and 
Bach1 binding to both E1 and E2 was reduced. 
These results suggest that the displacement of 
Nrf2 from E1 and E2 was not the result simply of 
the direct competitive binding between Nrf2 and 
MafK/Bach1. Consistent with this, we detected 
Smad2/3 on ARE (E2) in the presence of TGF-β 
signaling (Fig. 7). The exact molecular mechanism 
of MafK, Bach1, Smads and possibly MafG in the 
TGF-β-dependent suppression of HO-1 remains to 
be elucidated. 
  TGF-β markedly elevated expression of MafK 
and Bach1 in NMuMG cells. Transcriptional 
regulation of tissue-specific expression of the 
MafK gene was previously analyzed in transgenic 
mice harboring the lacZ gene as a reporter. Two 
alternative promoters were identified in the MafK 
gene, and the upstream and downstream promoters 
mediate the mesodermal and neuronal expressions, 
respectively (29, 30). A hematopoietic enhancer 
was also identified in the 3’ region of the MafK 
gene (31). However, the regulatory regions 
responsible for the induction by TGF-β have not 
been identified. We found that Smad4 was 
indispensable for the expression of MafK and 
suppression of HO-1 by TGF-β (Suppl. Fig. 1C, 
1E). Conversely, Bach1 expression was 
constitutitely activated by knockdown of Smad4 
(Suppl. Fig. 1E).  
  The regulatory mechanisms of Bach1 function 
identified so far are mainly at the 
posttranscriptional level, ie, changes in DNA 
binding affinity, subcellular localization, and 
protein stability (10, 32, 33). One report described 
the transcriptional regulation of BACH1 examined 
in a reporter assay in K562 cells (34). A GC box 
residing in the promoter region was critical for the 
promoter activity, and Sp1 was a transactivating 
factor binding to the GC box, which could be a 
target of TGF-β signaling. Transcriptional 
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regulation of Bach1 by TGF-β signaling might 
constitute a novel layer of the regulation of Bach1 
function in vivo. 
  TGF-β signaling is highly enhanced in many 
pathological conditions including precancerous 
lesions associated with ulcerative colitis and viral 
hepatitis (35, 36). The present study demonstrated 
that TGF-β markedly suppresses a cytoprotective 
gene, HO-1. It should be noted that a single 
nucleotide polymorphism in the enhancer region 
of HO-1, which affects HO-1 expression, has been 
implicated in an increased incidence of lung 
cancer (37). These molecular epidemiological data 
suggest that suppression of HO-1 may accelerate 
cancer initiation and progression. Therefore, 
TGF-β might promote cancer initiation in 
precancerous lesions or expedite cancer 
progression through suppression of Nrf2-target 
genes, including HO-1. 
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TABLES 
 
Table 1 Sequence information for interference RNA 
name sequence 
siRNA MafK 
#1 
sense 5’-CGAUGAUGAGCUGGUGUCCAUGUCA-3’ 
antisense 5’-UGACAUGGACACCAGCUCAUCAUCG-3’ 
siRNA MafK 
#2 
sense 5’-GGGCUAAUGUCUGUGUUCCUGUGUG-3’ 
antisense 5’-CACACAGGAACACAGACAUUAGCCC-3’ 
siRNA Bach1 
#1 
sense 5’-GAAGGCUGCUCAAGCAACUUGGAAA-3’ 
antisense 5’-UUUCCAAGUUGCUUGAGCAGCCUUC-3’ 
siRNA Bach1 
#2 
sense 5’-ACUGUGAGGUGAAGCUGCCAUUCAA-3’ 
antisense 5’-UUGAAUGGCAGCUUCACCUCACAGU-3’ 
 
  
 2 
Table 2 Primers for semi-quantitative PCR 
 
 
 
 
 
 
 
 
 
 
name  sequence 
product 
length 
(bp) 
annealing 
temperature 
(°C) 
Cycle 
number 
NQO1 
sense 5’-AGAAGAGAGGATGGGAGGTA-3’ 
354 55 25 
antisense 5’-TGGTGATAGAAAGCAAGGTC-3’ 
HO-1 
sense 5’-GGGTGACAGAAGAGGCTAAG-3’ 
319 55 22 
antisense 5’-CATTGGACAGAGTTCACAGC-3’ 
GCSH 
sense 5’-ATTGTTATGGCTTTGAGTGC-3’ 
353 55 25 
antisense 5’-GCATCATCCAGGTGTATTAA-3’ 
b-actin 
sense 5’-GCTCATAGCTCTTCTCCAGGG-3’ 
396 55 22 
antisense 5’-TGAACCCTAAGGCCAACCGTG-3’ 
MafF 
sense 5’-AACACGCCGCACCTGTCGGA-3’ 
194 55 25 
antisense 5’-GACTTCTGCTTCTGCAGCTC-3’ 
MafG 
sense 5’-AGAAGGAGGAGCTGGAGAAG-3’ 
257 55 25 
antisense 5’-GCATCCGTCTTGGACTTTAC-3’ 
MafK 
sense 5’-AGCGATGATGAGCTGGTGTC-3’ 
206 55 25 
antisense 5’-AGCTTCTCCACCTCCTGCTG-3’ 
Bach1 
sense 5’-GTGCAGAGTAAAACCGTGAA-3’ 
499 55 25 
antisense 5’-AGTCATCTCCCAGGCTAATC-3’ 
Smad7 
sense 5’-GGAAGTCAAGAGGCTGTGTT-3’ 
296 55 25 
antisense 5’-GTCTTCTCCTCCCAGTATGC-3’ 
 3 
Table 3 Primers for ChIP analysis 
name  sequence 
product 
length 
(bp) 
annealing 
temperature 
(°C)	 
Cycle 
number 
HO-1 
promoter 
(E1) 
sense 5’-TGAAGTTAAAGCCGTTCCGG-3’ 
183 53 35 
antisense 5’-AGCGGCTGGAATGCTGAGT-3’ 
HO-1 
promoter 
(E2) 
sense 5’-GGGCTAGCATGCGAAGTGAG-3’ 
201 53 35 
antisense 5’-AGACTCCGCCCTAAGGGTTC-3’ 
 4 
Table 4 Primers for ChIP analysis, qPCR 
name  sequence 
product 
length 
(bp) 
HO-1 
promoter 
(E2) 
sense 5’-GGGCAGTCTTAAGCAATCCA-3’ 
146 
antisense 5’-AAGGGTTCAGTCTGGAGCAA -3’ 
Smad7 
sense 5’-TAGAAACCCGATCTGTTGTTTGCG-3’ 
132 
antisense 5’-CCTCTGCTCGGCTGGTTCCACTGC-3’ 
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FIGURE LEGENDS 
 
FIGURE 1.  TGF-β suppresses tBHQ-inducible expression of the heme oxygenase-1 gene (HO-1). A 
TGF-β suppresses tBHQ-inducible mRNA expression of HO-1. NMuMG cells were treated with TGF-β 
(5 ng/ml) one hour before stimulation with tBHQ (25 µM) and incubated for the indicated times. HO-1 
and β-actin mRNAs were detected by semiquantitative RT-PCR (left panel). Representative mRNA 
expression was quantified using ImageJ (NIH) and normalized to β-actin (right panel). B NMuMG cells 
were treated as in A. Immunoblot analysis was performed using anti-HO-1 antibody. β-actin was 
examined as a loading control (left panel). Quantification of the protein levels was performed using 
ImageJ (NIH) and normalized to β-actin (right panel). All experiments were repeated more than three 
times to confirm their reproducibility.  
 
FIGURE 2.  TGF-β does not affect the stabilization and nuclear accumulation of Nrf2. A NMuMG cells 
were treated with TGF-β (5 ng/ml) for one hour before stimulation with tBHQ (25 µM) and incubated for 
4 more hours. Immunoblot analysis was performed using anti-Nrf2, phospho-Smad2, Smad2 and 
α-tubulin antibodies as indicated. Arrow: specific band for Nrf2. *: nonspecific bands. B NMuMG cells 
were treated as in A. After fixation, cells were serially stained with anti-Nrf2 (green) and anti-Smad2 (red) 
antibodies. Nuclei were counterstained with DAPI. Bar = 50 µm. C NMuMG cells were treated as in A. 
Nuclear and cytosolic fractions were isolated and analyzed by immunoblotting using antibodies for Nrf2 
and Smad2. Lamin A/C was used as a nuclear protein marker and α-tubulin, as a cytosolic protein marker.  
 
FIGURE 3.  TGF-β induces MafK and Bach1. A NMuMG cells were treated with TGF-β (5 ng/ml) for 
one hour. mRNA for the small Maf family of transcription factors (MafF, MafG, and MafK), Bach1, 
Smad7, and β-actin was detected by semiquantitative RT-PCR. B NMuMG cells were treated with TGF-β 
(5 ng/ml) for 4 hours. Immunoblot analysis was performed using anti-MafK, Bach1, phospho-Smad2, 
Smad2, and β-actin antibodies as indicated. Bach1 was detected after immunoprecipitation with 
anti-Bach1 antibody to increase the sensitivity. C NMuMG cells were treated with a TGF-β type I 
receptor kinase inhibitor, SD-208 (0, 0.03, 0.1, 0.3 µM) for 30 minutes before treatment with TGF-β (5 
ng/ml) for one hour. MafK, Bach1, Smad7, and β-actin mRNAs were detected by semiquantitative 
RT-RCR. 
 
FIGURE 4.  MafK and MafG but not MafF suppress transcriptional activity of HO-1. A pHO1-luc 
reporter activities were activated by overexpression of Nrf2 and the effects of MafF, MafG, and MafK 
examined. B Interaction between Nrf2 and small Mafs was examined by coprecipitation assays in 293T 
cells. MafF, MafG, and MafK all coprecipitated Nrf2. C Binding of small Mafs to antioxidant responsible 
elements (AREs) from HO-1. HA-tagged MafF, MafG, and MafK were expressed in 293T cells and the 
cell lysates, incubated with biotinylated ARE double-strand DNA fragments from HO-1 and precipitated 
with avidin beads. Coprecipitated proteins were detected with anti-HA antibody. D Chromatin 
immunoprecipitation analysis using anti-FLAG antibody detected binding of MafK and MafG to the HO-1 
promoter region including ARE(E2) in NMuMG-MafK(K) and NMuMG-MafG(G) cells, respectively. 
 
FIGURE 5.  MafK and Bach1 regulate expression of HO-1. A, B MafK suppresses HO-1 induction by 
tBHQ or DEM. A Establishment of NMuMG cells stably expressing FLAG-MafK (clones 4 and 10). 
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Control represents NMuMG cells transfected with empty vector. B Impaired induction of HO-1 in 
NMuMG-MafK cells. NMuMG-MafK cells were treated with tBHQ (25 µM) or DEM (100 µM) for 4 
hours. HO-1 and β-actin mRNAs were detected by semiquantitative RT-PCR. C pHO-1-luc activities are 
inactivated in NMuMG-MafK cells. Six hours after transfection with pHO-1-luc, cells were treated with 
tBHQ (25 µM) or DEM (100 µM) for 12 hours. Error bars represent mean ± SD. D Knockdown of MafK 
enhances induction of HO-1. NMuMG cells were transfected with MafK siRNA (#1 or #2) as described in 
Experimental Procedures. Cells were then treated with TGF-β (5 ng/ml) for one hour and then stimulated 
with tBHQ (25 µM) for 4 hours. HO-1, MafK, and β-actin mRNAs were detected by semiquantitative 
RT-PCR. E, F Bach1 suppresses induction of HO-1 by tBHQ and DEM. E Establishment of NMuMG 
cells stably expressing FLAG-Bach1 (clones 2 and 7). F Impaired induction of HO-1 in NMuMG-Bach1 
cells. NMuMG-Bach1 cells were treated with tBHQ (25 µM) or DEM (100 µM) for 4 hours. HO-1 and 
β-actin mRNAs were examined by semiquantitative RT-PCR. G pHO-1-luc activities are suppressed in 
NMuMG-Bach1 cells. Six hours after transfection with pHO-1-luc, cells were treated with tBHQ (25 µM) 
or DEM (100 µM) for 12 hours. Error bars represent mean ± SD. H Knockdown of Bach1 enhances 
induction of HO-1 and impairs the suppressive effects of TGF-β. NMuMG cells were transfected with 
Bach1 siRNA (#1 or #2) as described in Experimental Procedures. Cells were treated with TGF-β (5 
ng/ml) for one hour before treatment with tBHQ (25 µM) for 4 hours. HO-1, Bach1, and β-actin mRNAs 
were detected by semiquantitative RT-PCR. I Double-knockdown of MafK and Bach1 enhances induction 
of HO-1 and almost completely impairs the suppressive effects of TGF-β. NMuMG cells were transfected 
with MafK siRNA #1 and Bach1 siRNA #2 as described in Experimental Procedures. Cells were then 
treated with TGF-β (5 ng/ml) for one hour before treatment with tBHQ (25 µM) for 4 hours. HO-1, MafK, 
Bach1, and β-actin mRNAs were detected by semiquantitative RT-PCR. Representative mRNA 
expression was quantified using ImageJ (NIH) and normalized to β-actin (right panel). J Knockdown of 
MafK or Bach1 enhances expression of HO-1 in breast cancer cells. JygMC(A) cells were transfected with 
MafK siRNA or Bach1 siRNA as indicated. HO-1, MafK, Bach1 and β-actin mRNAs were detected by 
semiquantitative RT-RCR. 
 
FIGURE 6.  Effects of TGF-β on the recruitment of Nrf2, MafK, and Bach1 to AREs (E1 and E2) in the 
HO-1 promoter. NMuMG cells were treated with TGF-β (5 ng/ml) for one hour before stimulation with 
tBHQ (25 µM) for 4 hours. After fixation, soluble chromatin was immunoprecipitated using anti-Nrf2 (A), 
anti-MafK (B), or anti-Bach1 (C) antibodies as indicated. HO-1 promoter fragments containing AREs (E1 
or E2) were amplified by PCR. Input: total chromatin solution was analyzed as a control. 
 
FIGURE 7.  Cooperative functions of TGF-β/Smad signaling with MafK and Bach1. A, B Binding of 
Smad3 to MafK(A) and Bach1(B). FLAG-MafK, FLAG-Bach1, Myc-Smad3 and a constitutively active 
TGF-β type I receptor (ALK5TD-V5) were transfected to 293T cells as indicated, and binding of MafK or 
Bach1 and Smad3 were examined by immunoprecipitation with anti-Myc antibody followed by 
immunoblotting with anti-FLAG antibody. Arrow: Myc-Smad3. *: IgG. C, D Chromatin 
immunoprecipitation analyses using anti-Smad2/3 antibody detected binding of Smad2/3 to the HO-1 
promoter region including ARE(E2) in NMuMG cells (C). Binding of Smad2/3 to the Smad7 promoter 
region was used as a positive control (D). 
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Figure 5 (continued) 
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